Abstract
Objective To explore the clinical efficacy of trastuzumab combined with vinorelbine therapy in the treatment of advanced breast cancer with human epithelial growth factor receptor-2 (HER-2) positive. Methods From April 2010 to April 2013, 91 advanced breast cancer patients who failed in the paclitaxel therapy received trastuzumab plus vinorelbine (45 cases, vinorelbine group) or capecitabine (46 cases, capecitabine group). The treatment efficacy, toxic effects and 3-year survival rate in two groups were compared. Results The clinical benefit rate in two groups had no significant difference (P > 0.05), but objective response rates in vinorelbine group was higher than that in capecitabine group: 44.44%(20/45) vs. 23.91%(11/46), and there was significant difference (P= 0.039). The toxic effects in two groups had no significant difference (P > 0.05). The 3-year survival rate in two groups had no significant difference (P= 0.252). Conclusions In the treatment of HER-2 positive advanced breast cancer, trastuzumab plus vinorelbine or capecitabine shows no significant differences in adverse reaction or in 3-year survival rate. However, trastuzumab plus vinorelbine shows better objective response rate compared with trastuzumab plus capecitabine. Key words: Breast neoplasms; Trastuzumab; Vinorelbine; Capecitabine; Treatment outcome
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
